Rockefeller Capital Management’s BridgeBio Oncology BBOT Stock Holding History
Bought
Maintained
Sold
Other funds holding BBOT
Rockefeller Capital Management's BBOT Position: Q3 2026 in Review
Rockefeller Capital Management increased its BridgeBio Oncology (BBOT) stake by 100% in Q3 2026, buying an estimated $7.77K and bringing the position to 2,000 shares worth $8.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4237.
Rockefeller Capital Management first reported a position in BBOT in Q4 2025 and has held it in 4 quarters since. The position peaked at $8.76K in Q4 2025. 89 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.
- Rockefeller Capital Management held 2,000 shares of BridgeBio Oncology worth $8.2K as of Q3 2026.
- Rockefeller Capital Management bought 1,000 BridgeBio Oncology shares in Q3 2026, an estimated $7.77K.
- BridgeBio Oncology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4237 holding.
- Rockefeller Capital Management first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 4 quarters since.
- Rockefeller Capital Management's BridgeBio Oncology position peaked at $8.76K in Q4 2025.
- 89 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.